Oxycodone 15 mg Immediate-Release (IR)

Oxycodone is a semisynthetic opiate partial agonist derived from the opioid alkaloid, thebaine. Oxycodone 15 mg is used to control moderate to severe pain. It is available as immediate-release tablets (IR), extended-release (ER), and in combination with acetaminophen. Oxycodone undergoes low first-pass metabolism and has a higher bioavailability (60%-87%) compared with morphine. It is slightly more potent than morphine (Oral Oxycodone is roughly 1.5 times more potent than oral morphine).

Therapeutic Fields​

Fast Relief of Acute Pain

Acute pain relief

Fast onset of action

For initial dose in opioid-naive patients

Clinical Research

Oral Oxycodone 15 mg is as effective as IV Morphine Sulfate (MS) in the Management of Acute Pain Following limb trauma.

Based on a clinical trial performed in 2018 there was no significant difference between the two groups regarding the decrease in pain within 0, 30, and 60 minutes after administration of either 5mg IV MS or 5mg oral oxycodone. Drowsiness was reported more frequently in the MS group after 30 minutes. Eight participants asked for rescue analgesia in the MS group, while only one patient asked for more analgesia in Oxycodone 15 mg. Other adverse effects were similar in both groups.​

Calculating Total Daily Dose of Oxycodone 15 mg for Safer Dosage

Calculating total daily doses of opioids is important to appropriately and effectively prescribe, manage, and taper opioid medications. Patients prescribed higher opioid dosages are at higher risk of overdose death. The daily dose calculation of new opioids is as follows

Total Daily Dose of New Opioid

The obtained total daily dose divided by 2 is for OXYCODONE ER and divided by 4 is for OXYCODONE IR. These dose conversions are estimated and cannot account for all individual differences in genetics and pharmacokinetics.

Dosing

Infants ≤ 6 months:

Oral Initial dose: 0.025 to 0.05 mg/ kg/ dose every 4 to 6 hours as needed.

Infants> 6 months, Children:

Patient weight <50 kg: Initial dose: 0.1 to 0.2 mg/ kg/ dose every 4 to 6 hours as needed.

Adolescents:

Patient weight 2:50 kg. Initial dose: 5 to 10 mg every 4 to 6 hours as needed.

Administration

Onset

5 – 15 min

Half-life

3.2, 4 h

Maximum Dose

320 mg/day

The recommended dose of ER Cap oxycodone base is 288 mg/ day and 9mg oxycodone-based equivalent to 10mg oxycodone hydrochloride.

Contraindication

• Hypersensitivity to Oxycodone 15 mg or other
• Patients with circulatory shock and
• Significant respiratory depression, acute or severe bronchial asthma, moderate to severe sleep disorder
• Known or suspected paralytic ileus and gastrointestinal
• not recommended during pregnancy and breast

Warning and Precautions

• Use with caution: in CNS depression, Severe hypotension, Respiratory depression, Seizures, Constipation, Mental health conditions, Obesity, Thyroid dysfunction, adrenal insufficiency, Prostatic hyperplasia/urinary stricture, acute alcoholism, underlying GI disorders, difficulty in swallowing, Pancreatic and Biliary disease, Head trauma, Hepatic and renal impairment G6PD deficiency.
• Cytochrome P450 3A4 inhibitors: The concomitant use may increase in oxycodone plasma
• Hepatotoxicity: Most of the cases of liver injury are associated with the use of Acetaminophen at doses that exceed 4g/day in
• Skin reactions: Discontinue therapy at the first appearance of skin rash.

Drug Interactions

• Risk X: Abametapir, Azelastine (Nasal), Bromperidol, Eluxadoline, Fusidic Acid, MAOls, opioids (Mixed Agonist/ Antagonist), Orphenadrine, paraldehyde, Samidorphan,
• SSRls, SNRls, MAOls, 5-HT1, 3 receptor antagonists, Buspirone, Dextromethorphan, Lithium, Cyclobenzaprine, linezolid, John’s wort: concomitant use may cause serotonin syndrome.
• CNS depressants (other opioid analgesics, general anesthetics, phenothiazines, tranquilizers, centrally-acting anti-emetics, sedative-hypnotics, and alcohol): concomitant use may cause hypotension, respiratory depression, and coma.

Side Effects

• Drowsiness, headache, dizziness, Pruritus, Nausea, constipation, vomiting, Fever

As a manufacturer, Pluvia Endo can supply you in grades like USP and BP at competitive prices with the best quality material with Unique Molecules & Know-How. Our Portfolio Contains Several Specific APIs & Finished Dosage Form Medications in The Field of Opioid Medications & Nutraceutical Supplements.

Contact us for more information